Introducing PolyV-2
Prosthetic polymeric aortic valve optimized for Transcatheter Aortic Valve Replacement (TAVR) procedures
Using a combination of state-of the-art polymers and unique design optimization approach (DTE), PolyNova transcatheter heart valve technology addresses the intrinsic limitations of current tissue- based valve products
​
PolyV-2 is a modification of our first-generation valve PolyV-1
Features & Benefits:
-
Suture-less - valve is molded with the stent
-
Engineering flexibility and precision manufacturing
-
Superior hydrodynamic performance
-
Minimal thrombogenicity profile
-
Design optimized for extended durability
-
Resistance to crimping damage
-
Minimum susceptibility to calcific deposition
-
Lower cost and reproducible mass production
PolyNova does not currently market or sell any medical devices. The FDA has not approved any PolyNova products for use in the United States of America. PolyNova does not hold any CE Marks. This website may contain forward-looking statements and is for informational purposes only.